| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | Consolidated revenue at ₹2,037.1 Cr, pharmacy up 21.3% YoY. |
|---|---|
| Margins | EBITDA margin at 4.8%; impacted by Karnataka/Telangana wage revisions. |
| Demand visibility | Strong pharmacy demand; diagnostics segment revenue grew to ₹41.1 Cr. |
| Management confidence | Balanced; focused on cost consolidation after unexpected regulatory wage headwinds. |
Growth
Revenue grew significantly YoY, driven by store expansions and private label non-pharma sales rising to 10.7% mix.
Outlook
Management targets ₹380-400 Cr annual EBITDA for FY27 and expects private label mix to grow 0.5% quarterly.
Risks
Substantial ₹80-85 Cr annual impact from minimum wage hikes in Karnataka and Telangana pressures margins.
Last quarter's promises, checked
Delivered
- Non-pharma supply fix, full impact by Q-end → non-pharma +18% QoQ (= BEAT)
- Discount cut 20%→19% on >₹1,000 bills from 7 Jul → cut implemented (= BEAT)
Partly delivered
- 800 net store adds FY27 → network 5,476 (Q1) → 5,642 (Q2) (= PARTIAL)
- AOP EBITDA ~₹400 Cr, 'no change' → ₹380–400 Cr guide (= PARTIAL)
- Margin back to ~9% (analyst's figure) → EBITDA 4.8% vs 3.5% in Q1 (= PARTIAL)
Missed
- 2.5–3.0 lakh diagnostic members by now → 2.16 lakh (= MISS)
Earnings Call Transcript filed with BSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹609.40
- Market cap
- ₹7,321 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 34.7×Sector 52.0×
- Promoter holding
- 40.19%+0.00% QoQ
- FII holding
- 12.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Share Pledge
Catalyst Trusteeship pledged 34,00,000 Medplus Health Services shares (2.83%) as debenture collateral. Total encumbered shares rose to 2,41,50,400 (20.10% of capital).
Medplus Health Services Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹2,037cr (+21.3% YoY), operating EBITDA ₹98cr (4.8% margin), reported PAT ₹56cr (+1% YoY). Store expansion continues; no explicit guidance given.
Medplus Health Services Employee Stock Options
MedPlus allotted 19,095 equity shares to employees on exercise of ESOP 2021 options. Paid-up capital rises to Rs 24.03 Crore.
Medplus Health Services Q2 FY27 Results: Net Profit ₹56.1 Cr, Up 1.1% YoY
Medplus Health Services Ltd reported revenue from operations of ₹2,037 Cr (+21.3% YoY) and net profit of ₹56.1 Cr (+1.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.1 Cr · +1.1% YoY
Medplus Health Services Adverse Business Impact
Optival Health, a MedPlus subsidiary, had drug licences suspended at five Karnataka stores for 1–7 days. Expected impact is about Rs 8.66 lakhs.
- Value
- ₹0.09 Cr
- Execution
- 1 to 7 days per store
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary Optival Health faced temporary drug license suspensions for two stores by Mysore regulators. The estimated operational impact is ₹0.02 Crore.
- Value
- ₹0.02 Cr